Argenx

This study looked at whether adults with CIDP, a nerve condition that causes weakness, can switch from regular IV infusions to a new shot called efgartigimod PH20 SC. 23 people who were stable on IVIg took part. The goal was to see if they could stay on the new treatment for 12 w…

This study tested a new drug called ARGX-117 in 54 adults with multifocal motor neuropathy (MMN), a condition that causes muscle weakness. Participants were already stable on regular IVIg treatments. The goal was to see if ARGX-117 could safely delay or replace the need for IVIg.…

This study tested the long-term safety of a drug called efgartigimod, given as a shot under the skin, in 184 adults with generalized myasthenia gravis (a condition that causes muscle weakness). Participants received repeated treatment cycles as needed. The main goal was to check …

This study looked at two ways of giving the drug efgartigimod to people with generalized myasthenia gravis, a condition that causes muscle weakness. One group received the drug on a continuous schedule, while the other received it in cycles. The goal was to see which approach bet…

This study tested a drug called efgartigimod in 101 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The goal was to see if the drug is safe and helps maintain healthy platelet levels over a year. P…

This study tested a drug called efgartigimod in 98 adults with moderate to severe bullous pemphigoid, a condition that causes painful blisters and itching. The goal was to see if the drug could help people achieve complete remission (no new blisters, healed skin, no itching) whil…

This study looks at the long-term safety of a drug called efgartigimod for adults with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. Participants had already completed a previous efgartigimod study. The drug works by lowering harmful antibodies…

This study tested a drug called efgartigimod in 73 Chinese adults with active lupus nephritis, a kidney disease caused by lupus. The goal was to see if the drug could reduce protein in the urine and improve kidney function over 24 weeks. Participants received either the drug or a…

This early-stage study tested a single dose of ARGX-109 in 40 healthy adults to see if it is safe and how the body processes it. Participants were monitored for about 20 weeks. The goal was to gather safety data, not to treat any disease.

This early-stage study tested the safety of a new drug called ARGX-213 in 88 healthy adults. Researchers measured how the drug moves through the body and checked for side effects. Participants were monitored for up to 21 weeks. This study does not aim to treat any disease.